臨床試験の総合的な結果は,すべての患者に適用できますか?
1Department of Clinical Neuroscience, Western General Hospital, Edinburgh, UK.
Lancet (London, England)
|June 24, 1995
まとめ
臨床試験の結果は,すべての患者に等しく適用されない場合があります. 治療の有効性は,個々の脳卒中リスクによって異なりますが,最適な患者候補者を特定することで,医療の費用対効果に影響を及ぼします.
科学分野:
- 臨床流行病学 臨床流行病学とは
- 医療統計の医療統計について
背景:
- 臨床試験の結果は,一貫した相対的な治療効果を想定して,通常,すべての患者に一般化されます.
- 臨床実務において極めて重要なこの仮定は,めったに検証されていない.
- 多様な患者集団に対する臨床試験結果の汎用性は,依然として重要な考慮事項です.
研究 の 目的:
- 臨床試験における相対的な治療効果が,患者の脳卒中の絶対的ベースラインリスクによって変化するかどうかを調査する.
- 主要な臨床試験における治療効果の異質性を評価する.
- 予後モデルが治療効果の変動を特定できるかどうかを判断する.
主な方法:
- 欧州頸動脈外科試験と英国-TIAアスピリン試験からのデータの再分析.
- ベースライン脳卒中リスクを予測するために,独立して派生した予後モデルを利用した.
- 相対的な治療効果と絶対的なベースラインリスクの関連性を調べました.
主要な成果:
- 両試験で相対的な治療効果の有意な異質性が観察されました.
- 絶対的な治療効果は,予期されたベースライン脳卒中リスクに基づいて大幅に変化しました.
- 患者の個々のリスクは,治療から得られる実際の利益に大きな影響を与えました.
結論:
- 臨床試験におけるすべての患者に対して治療効果が均一であるという仮定は,しばしば無効である.
- ベースラインリスクと治療効果の関係を理解することで,医療介入を最適化することができます.
- 恩恵を受けない,または最大限の恩恵を受ける患者のサブグループを特定することで,費用対効果が向上します.
さらに関連する動画
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
04:11A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
Published on: June 9, 2026
関連する概念動画
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...